76-LB: Baseline A1C Values and Magnitude of A1C Reductions during Nonadjunctive Continuous Glucose Monitoring Use in the COACH Study

Abstract

The Continuous Monitoring and Control of Hypoglycemia study aimed to evaluate use of a continuous glucose monitoring (CGM) system in adults with insulin-requiring diabetes who were new to CGM. The study design called for a 6-month phase in which insulin dosing decisions were based on self-monitored blood glucose (SMBG) values followed by a 6-month phase in which diabetes management decisions were based on nonadjunctive use of a Dexcom CGM. Patients were followed via usual care aside from monthly phone calls to document severe hypoglycemia and DKA. Changes in A1C were a secondary outcome. A1C values were available at 6 and 12 months from 517 individuals in the per-protocol population. There was a trend toward larger A1C reductions among individuals with higher baseline (Month 0) A1C values (Figure). Although the mean A1C was unchanged (Month 6 to Month 12) for those with baseline A1C values Disclosure S. Beck: Employee; Self; Dexcom, Inc. C. Kelly: Consultant; Self; Ajinomoto Co., Inc., Dexcom, Inc., Hitachi, Ltd., Vascular Dynamics Inc. N. Njeru: None. J. Gorelick: Employee; Self; Dexcom, Inc., Edwards Lifesciences. J. C. Bowers: Employee; Self; Dexcom, Inc. D. A. Price: Employee; Self; Dexcom, Inc.